TY - JOUR AU - Phillips, L. S. AU - Grunberger, G. AU - Miller, E. AU - Patwardhan, R. AU - Rappaport, E. B. AU - Salzman, A. PY - 2001 DA - 2001// TI - Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes JO - Diabetes Care VL - 24 UR - https://doi.org/10.2337/diacare.24.2.308 DO - 10.2337/diacare.24.2.308 ID - Phillips2001 ER - TY - JOUR AU - Aronoff, S. AU - Rosenblatt, S. AU - Braithwaite, S. AU - Egan, J. W. AU - Mathisen, A. L. AU - Schneider, R. L. PY - 2000 DA - 2000// TI - Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose–response study. The Pioglitazone 001 Study Group JO - Diabetes Care VL - 23 UR - https://doi.org/10.2337/diacare.23.11.1605 DO - 10.2337/diacare.23.11.1605 ID - Aronoff2000 ER - TY - STD TI - Pharmaceutical benefit scheme medicine listing. Department of Health and Ageing. Australian Government. Available from: http://www.pbs.gov.au/browse/medicine-listing. (accessed December 20, 2012) UR - http://www.pbs.gov.au/browse/medicine-listing ID - ref3 ER - TY - JOUR AU - Nissen, S. E. AU - Wolski, K. PY - 2007 DA - 2007// TI - Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes JO - N Engl J Med VL - 356 UR - https://doi.org/10.1056/NEJMoa072761 DO - 10.1056/NEJMoa072761 ID - Nissen2007 ER - TY - JOUR AU - Home, P. D. AU - Pocock, S. J. AU - Beck-Nielsen, H. AU - Gomis, R. AU - Hanefeld, M. AU - Jones, N. P. AU - Komajda, M. AU - McMurray, J. J. PY - 2007 DA - 2007// TI - Rosiglitazone evaluated for cardiovascular outcomes–an interim analysis JO - N Engl J Med VL - 357 UR - https://doi.org/10.1056/NEJMoa073394 DO - 10.1056/NEJMoa073394 ID - Home2007 ER - TY - JOUR AU - Bilik, D. AU - McEwen, L. N. AU - Brown, M. B. AU - Selby, J. V. AU - Karter, A. J. AU - Marrero, D. G. AU - Hsiao, V. C. AU - Tseng, C. W. AU - Mangione, C. M. AU - Lasser, N. L. AU - Crosson, J. C. AU - Herman, W. H. PY - 2010 DA - 2010// TI - Thiazolidinediones, cardiovascular disease and cardiovascular mortality: translating research into action for diabetes (TRIAD) JO - Pharmacoepidemiol Drug Saf VL - 19 UR - https://doi.org/10.1002/pds.1954 DO - 10.1002/pds.1954 ID - Bilik2010 ER - TY - JOUR AU - Gerrits, C. M. AU - Bhattacharya, M. AU - Manthena, S. AU - Baran, R. AU - Perez, A. AU - Kupfer, S. PY - 2007 DA - 2007// TI - A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetes JO - Pharmacoepidemiol Drug Saf VL - 16 UR - https://doi.org/10.1002/pds.1470 DO - 10.1002/pds.1470 ID - Gerrits2007 ER - TY - STD TI - FDA: Briefing Information for the July 13–14, 2010 Joint Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee. Available from: http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm218491.htm. (accessed April 6, 2014) UR - http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm218491.htm ID - ref8 ER - TY - JOUR AU - Weatherby, L. B. AU - Nordstrom, B. L. AU - Fife, D. AU - Walker, A. M. PY - 2002 DA - 2002// TI - The impact of wording in “Dear doctor” letters and in black box labels JO - Clin Pharmacol Ther VL - 72 UR - https://doi.org/10.1067/mcp.2002.129503 DO - 10.1067/mcp.2002.129503 ID - Weatherby2002 ER - TY - STD TI - FDA: Advisory Committee. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM218493.pdf. (accessed April 6, 2014) UR - http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM218493.pdf ID - ref10 ER - TY - STD TI - Therapeutic Goods Administralion. About the TGA. Available from: http://www.tga.gov.au/about/committees-acsom.htm. (accessed May 30, 2012) UR - http://www.tga.gov.au/about/committees-acsom.htm ID - ref11 ER - TY - STD TI - FDA: Drug Safety Communication. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm199082.htm. (accessed Dec 20, 2012) UR - http://www.fda.gov/Drugs/DrugSafety/ucm199082.htm ID - ref12 ER - TY - STD TI - European Medicines Agency: News, press release and public statement archive. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/landing/news_search_landing_page.jsp&murl=menus/news_and_events/news_and_events.jsp&mid=WC0b01ac058004d5c1. (accessed on Nov 12, 2012) UR - http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/landing/news_search_landing_page.jsp&murl=menus/news_and_events/news_and_events.jsp&mid=WC0b01ac058004d5c1 ID - ref13 ER - TY - STD TI - PBS Latest News. Changes to listings for ROSIGLITAZONE MALEATE (Avandia®) and ROSIGLITAZONE MALEATE with METFORMIN HYDROCHLORIDE (Avandamet®)-1 November 2008. Available from: http://www.pbs.gov.au/info/news/2008/11/List-amndmnts-avandia-avandamet (accessed May 10, 2012) UR - http://www.pbs.gov.au/info/news/2008/11/List-amndmnts-avandia-avandamet ID - ref14 ER - TY - STD TI - Pharmaceutical Benefits Advisory Committee. Positive Recommendations made by the PBAC — March 2011. 2011, Canberra: Australian Government Department of Health and Ageing, Available from: http://www.pbs.gov.au/info/publication/factsheets/professional/new-listings-and-changes-1-july-2011 (accessed April 6, 2014) UR - http://www.pbs.gov.au/info/publication/factsheets/professional/new-listings-and-changes-1-july-2011 ID - ref15 ER - TY - JOUR AU - Lincoff, A. M. AU - Wolski, K. AU - Nicholls, S. J. AU - Nissen, S. E. PY - 2007 DA - 2007// TI - Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials JO - JAMA VL - 298 UR - https://doi.org/10.1001/jama.298.10.1180 DO - 10.1001/jama.298.10.1180 ID - Lincoff2007 ER - TY - JOUR AU - Erdmann, E. AU - Spanheimer, R. AU - Charbonnel, B. PY - 2010 DA - 2010// TI - Pioglitazone and the risk of cardiovascular events in patients with Type 2 diabetes receiving concomitant treatment with nitrates, renin-angiotensin system blockers, or insulin: results from the PROactive study (PROactive 20) JO - J Diabetes VL - 2 UR - https://doi.org/10.1111/j.1753-0407.2010.00082.x DO - 10.1111/j.1753-0407.2010.00082.x ID - Erdmann2010 ER - TY - STD TI - AFSSAPS. Available from: http://ansm.sante.fr/var/ansm_site/storage/original/application/3b70d267800de891b8f204f0376b7538.pdf. (accessed May 30, 2012) UR - http://ansm.sante.fr/var/ansm_site/storage/original/application/3b70d267800de891b8f204f0376b7538.pdf ID - ref18 ER - TY - JOUR AU - Lewis, J. D. AU - Ferrara, A. AU - Peng, T. AU - Hedderson, M. AU - Bilker, W. B. AU - Quesenberry, C. P. AU - Vaughn, D. J. AU - Nessel, L. AU - Selby, J. AU - Strom, B. L. PY - 2011 DA - 2011// TI - Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study JO - Diabetes Care VL - 34 UR - https://doi.org/10.2337/dc10-1068 DO - 10.2337/dc10-1068 ID - Lewis2011 ER - TY - JOUR AU - Mamtani, R. AU - Haynes, K. AU - Bilker, W. B. AU - Vaughn, D. J. AU - Strom, B. L. AU - Glanz, K. AU - Lewis, J. D. PY - 2012 DA - 2012// TI - Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study JO - J Natl Cancer Inst VL - 104 UR - https://doi.org/10.1093/jnci/djs328 DO - 10.1093/jnci/djs328 ID - Mamtani2012 ER - TY - STD TI - European Medicines Agency: Press release. European Medicines Agency recommends new contraindications and warnings for pioglitazone to reduce small increassed risk of bladder cancer. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2011/07/WC500109176.pdf. (accessed May 30, 2012) UR - http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2011/07/WC500109176.pdf ID - ref21 ER - TY - STD TI - TGA: Pioglitazone and risk of bladder cancer. Safety advisory. Available from: http://www.tga.gov.au/safety/alerts-medicine-pioglitazone-110718.htm. (accessed Dec 12, 2012) UR - http://www.tga.gov.au/safety/alerts-medicine-pioglitazone-110718.htm ID - ref22 ER - TY - STD TI - FDA Drug Safety Communication: Update to ongoing safety review of Actos (pioglitazone) and increased risk of bladder cancer. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm259150.htm. (accessed Dec 20, 2012) UR - http://www.fda.gov/Drugs/DrugSafety/ucm259150.htm ID - ref23 ER - TY - JOUR AU - Starner, C. I. AU - Schafer, J. A. AU - Heaton, A. H. AU - Gleason, P. P. PY - 2008 DA - 2008// TI - Rosiglitazone and pioglitazone utilization from January 2007 through May 2008 associated with five risk-warning events JO - J Manag Care Pharm VL - 14 ID - Starner2008 ER - TY - JOUR AU - Cohen, A. AU - Rabbani, A. AU - Shah, N. AU - Alexander, G. C. PY - 2010 DA - 2010// TI - Changes in glitazone use among office-based physicians in the U.S., 2003–2009 JO - Diabetes Care VL - 33 UR - https://doi.org/10.2337/dc09-1834 DO - 10.2337/dc09-1834 ID - Cohen2010 ER - TY - JOUR AU - Stewart, K. A. AU - Natzke, B. M. AU - Williams, T. AU - Granger, E. AU - Casscells, S. W. AU - Croghan, T. W. PY - 2009 DA - 2009// TI - Temporal trends in anti-diabetes drug use in TRICARE following safety warnings in 2007 about rosiglitazone JO - Pharmacoepidemiol Drug Saf VL - 18 UR - https://doi.org/10.1002/pds.1819 DO - 10.1002/pds.1819 ID - Stewart2009 ER - TY - JOUR AU - Ruiter, R. AU - Visser, L. E. AU - van Herk-Sukel, M. P. AU - Geelhoed-Duijvestijn, P. H. AU - Bie, S. D. AU - Straus, S. M. AU - Mol, P. G. AU - Romio, S. A. AU - Herings, R. M. AU - Stricker, B. H. PY - 2012 DA - 2012// TI - Prescribing of Rosiglitazone and Pioglitazone Following Safety Signals: Analysis of Trends in Dispensing Patterns in the Netherlands from 1998 to 2008 JO - Drug Saf VL - 35 UR - https://doi.org/10.2165/11596950-000000000-00000 DO - 10.2165/11596950-000000000-00000 ID - Ruiter2012 ER - TY - STD TI - WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index. Available from: http://www.whocc.no/atc_ddd_index/. (accessed Nov 23, 2011) UR - http://www.whocc.no/atc_ddd_index/ ID - ref28 ER - TY - STD TI - Australian Goverment Department of Health and Ageing. About PBS. Available from: http://pbs.gov.au/info/about-the-pbs (accessed November 30, 2011) UR - http://pbs.gov.au/info/about-the-pbs ID - ref29 ER - TY - JOUR AU - Hollingworth, S. AU - Duncan, E. L. AU - Martin, J. H. PY - 2010 DA - 2010// TI - Marked increase in proton pump inhibitors use in Australia JO - Pharmacoepidemiol Drug Saf VL - 19 UR - https://doi.org/10.1002/pds.1969 DO - 10.1002/pds.1969 ID - Hollingworth2010 ER - TY - JOUR AU - Islam, M. M. AU - Conigrave, K. M. AU - Day, C. A. AU - Nguyen, Y. AU - Haber, P. S. PY - 2014 DA - 2014// TI - Twenty-year trends in benzodiazepine dispensing in the Australian population JO - Intern Med J VL - 44 UR - https://doi.org/10.1111/imj.12315 DO - 10.1111/imj.12315 ID - Islam2014 ER - TY - STD TI - Centrelink. Department of Human Services. Australian Government. Available from: http://www.humanservices.gov.au/. (accessed July 20, 2012) UR - http://www.humanservices.gov.au/ ID - ref32 ER - TY - STD TI - Australian Bureau of Statistics. Available from: http://www.abs.gov.au/. (accessed July 20, 2012) UR - http://www.abs.gov.au/ ID - ref33 ER - TY - STD TI - TGA: Safety information. Available from: http://www.tga.gov.au/hp/information-safety.htm. (accessed Dec 12, 2012) UR - http://www.tga.gov.au/hp/information-safety.htm ID - ref34 ER - TY - STD TI - European Medicines Agency: News and events. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/landing/news_and_events.jsp&mid=. (accessed May 30, 2012) UR - http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/landing/news_and_events.jsp&mid= ID - ref35 ER - TY - STD TI - Food and Drug Administation: Drug Safety Communications. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm199082.htm. (accessed May 30, 2012) UR - http://www.fda.gov/Drugs/DrugSafety/ucm199082.htm ID - ref36 ER - TY - STD TI - TGA: Australian Adverse Drug Reactions Bulletin, Vol 26, No 6. Available from: http://www.tga.gov.au/hp/aadrb-0712.htm. (accessed Dec 20, 2012) UR - http://www.tga.gov.au/hp/aadrb-0712.htm ID - ref37 ER - TY - STD TI - TGA: Safety information. Rosiglitazone (Avandia/Avandamet). Advisory statement. Available from: http://www.tga.gov.au/safety/alerts-medicine-rosiglitazone-100924.htm. (accessed Nov 20, 2012) UR - http://www.tga.gov.au/safety/alerts-medicine-rosiglitazone-100924.htm ID - ref38 ER - TY - STD TI - FDA: Postmarket Drug Safety Information for Patients and Providers. Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm143349.htm. (accessed Dec 20, 2012) UR - http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm143349.htm ID - ref39 ER - TY - STD TI - FDA Drug Safety Communication. FDA Issues Safety Alert on Avandia. Available from: http://www.fda.gov/newsevents/newsroom/pressannouncements/2007/ucm108917.htm. (accessed April 6, 2014) UR - http://www.fda.gov/newsevents/newsroom/pressannouncements/2007/ucm108917.htm ID - ref40 ER - TY - STD TI - FDA: Avandia label. Available from: http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM143413.pdf. (accessed Dec 20, 2012) UR - http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM143413.pdf ID - ref41 ER - TY - STD TI - FDA significant restricts access to the diabetes drug Avandia. Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm226956.htm. (accessed Dec 20, 2012) UR - http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm226956.htm ID - ref42 ER - TY - STD TI - European Medicines Agency: Press release on May 23, 2007. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2009/11/WC500013467.pdf. (accessed May 15, 2011) UR - http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2009/11/WC500013467.pdf ID - ref43 ER - TY - STD TI - European Medicines Agency: Press release on October 18, 2007. Available from: http://www.emea.europa.eu/docs/en_GB/document_library/Press_release/2009/11/WC500011009.pdf. (accessed May 15, 2011) UR - http://www.emea.europa.eu/docs/en_GB/document_library/Press_release/2009/11/WC500011009.pdf ID - ref44 ER - TY - STD TI - European Medicines Agency: Press release on January 24, 2008. Available from: http://www.emea.europa.eu/docs/en_GB/document_library/Press_release/2009/11/WC500015420.pdf. (accessed May 15, 2012) UR - http://www.emea.europa.eu/docs/en_GB/document_library/Press_release/2009/11/WC500015420.pdf ID - ref45 ER - TY - STD TI - European Medicines Agency: European Medicines Agency recommends suspension of Avandia, Avandamet and Avaglim. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2010/09/news_detail_001119.jsp&mid=WC0b01ac058004d5c1&jsenabled=true. (accessed May 30, 2012) UR - http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2010/09/news_detail_001119.jsp&mid=WC0b01ac058004d5c1&jsenabled=true ID - ref46 ER - TY - JOUR PY - 1975 DA - 1975// TI - Intervention analysis with applications to economic and environmental problems JO - J Am Stat Assoc VL - 70 UR - https://doi.org/10.1080/01621459.1975.10480264 DO - 10.1080/01621459.1975.10480264 ID - ref47 ER - TY - JOUR AU - Shah, N. D. AU - Montori, V. M. AU - Krumholz, H. M. AU - Tu, K. AU - Alexander, G. C. AU - Jackevicius, C. A. PY - 2010 DA - 2010// TI - Responding to an FDA warning–geographic variation in the use of rosiglitazone JO - N Engl J Med VL - 363 UR - https://doi.org/10.1056/NEJMp1011042 DO - 10.1056/NEJMp1011042 ID - Shah2010 ER - TY - JOUR AU - Hurren, K. M. AU - Taylor, T. N. AU - Jaber, L. A. PY - 2011 DA - 2011// TI - Antidiabetic prescribing trends and predictors of thiazolidinedione discontinuation following the 2007 rosiglitazone safety alert JO - Diabetes Res Clin Pract VL - 93 UR - https://doi.org/10.1016/j.diabres.2011.02.035 DO - 10.1016/j.diabres.2011.02.035 ID - Hurren2011 ER - TY - STD TI - Australian Government Department of Health and Ageing: March 2008 PBAC Outcomes — Positive Recommendations made by the PBAC-November 2008. Available from: http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/pbac-outcomes/2008-11/positive-recommendations (accessed May 30, 2012) UR - http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/pbac-outcomes/2008-11/positive-recommendations ID - ref50 ER - TY - JOUR AU - Leal, I. AU - Romio, S. A. AU - Schuemie, M. AU - Oteri, A. AU - Sturkenboom, M. AU - Trifiro, G. PY - 2013 DA - 2013// TI - Prescribing pattern of glucose lowering drugs in the United Kingdom in the last decade: a focus on the effects of safety warnings about rosiglitazone JO - Br J Clin Pharmacol VL - 75 ID - Leal2013 ER - TY - JOUR AU - Kostapanos, M. S. AU - Elisaf, M. S. AU - Mikhailidis, D. P. PY - 2012 DA - 2012// TI - Pioglitazone and cancer: angel or demon? JO - Curr Pharm Des VL - 19 UR - https://doi.org/10.2174/13816128113199990294 DO - 10.2174/13816128113199990294 ID - Kostapanos2012 ER - TY - JOUR AU - Buckley, N. A. AU - Rossi, S. PY - 2011 DA - 2011// TI - Bringing greater transparency to “black box” warnings JO - Clin Toxicol (Phila) VL - 49 UR - https://doi.org/10.3109/15563650.2011.593523 DO - 10.3109/15563650.2011.593523 ID - Buckley2011 ER - TY - JOUR AU - Esterly, J. S. AU - Steadman, E. AU - Scheetz, M. H. PY - 2011 DA - 2011// TI - Impact of the FDA warning of potential ceftriaxone and calcium interactions on drug use policy in clinical practice JO - Int J Clin Pharm VL - 33 UR - https://doi.org/10.1007/s11096-011-9503-4 DO - 10.1007/s11096-011-9503-4 ID - Esterly2011 ER - TY - JOUR AU - Sen, E. F. AU - Verhamme, K. M. AU - Felisi, M. AU - t Jong, G. W. AU - Giaquinto, C. AU - Picelli, G. AU - Ceci, A. AU - Sturkenboom, M. C. PY - 2011 DA - 2011// TI - Effects of safety warnings on prescription rates of cough and cold medicines in children below 2 years of age JO - Br J Clin Pharmacol VL - 71 UR - https://doi.org/10.1111/j.1365-2125.2010.03860.x DO - 10.1111/j.1365-2125.2010.03860.x ID - Sen2011 ER - TY - STD TI - The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1472-6963/14/151/prepub UR - http://www.biomedcentral.com/1472-6963/14/151/prepub ID - ref56 ER -